|Other Names||Interleukin-1 receptor antagonist protein, IL-1RN, IL-1ra, IRAP, ICIL-1RA, IL1 inhibitor, Anakinra, IL1RN, IL1F3, IL1RA|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP6503a was selected from the Center region of human IL1RN. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||Synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml DI water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Function||Inhibits the activity of interleukin-1 by binding to receptor IL1R1 and preventing its association with the coreceptor IL1RAP for signaling. Has no interleukin-1 like activity. Binds functional interleukin-1 receptor IL1R1 with greater affinity than decoy receptor IL1R2; however, the physiological relevance of the latter association is unsure.|
|Cellular Location||Isoform 1: Secreted. Isoform 3: Cytoplasm.|
|Tissue Location||The intracellular form of IL1RN is predominantly expressed in epithelial cells|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The protein is a member of the interleukin 1 cytokine family. This protein inhibits the activities of interleukin 1, alpha (IL1A) and interleukin 1, beta (IL1B), and modulates a variety of interleukin 1 related immune and inflammatory responses. A polymorphism of its gene is reported to be associated with increased risk of osteoporotic fractures and gastric cancer.
Kumar,S., Biochem. Biophys. Res. Commun. 387 (3), 456-460 (2009)Rechcinski,T., Kardiol Pol 67 (6), 601-610 (2009)
If you have any additional inquiries please email technical services at firstname.lastname@example.org.